LAHCF | Health Care Fund | Lord Abbett
Image alt tag

Error!

There was a problem contacting the server. Please try after sometime.

Sorry, we are unable to process your request.

Error!

We're sorry, but the Insights and Intelligence Tool is temporarily unavailable

If this problem persists, or if you need immediate assistance, please contact Customer Service at 1-888-522-2388.

Error!

We're sorry, but the Literature Center checkout function is temporarily unavailable.

If this problem persists, or if you need immediate assistance, please contact Customer Service at 1-888-522-2388.

Tracked Funds

You have 0 funds on your mutual fund watch list.

Begin by selecting funds to create a personalized watch list.

(as of 12/05/2015)

Pending Orders

You have 0 items in your cart.

Subscribe and order forms, fact sheets, presentations, and other documents that can help advisers grow their business.

Reset Your Password

Financial Professionals*

Your password must be a minimum of characters.

Confirmation Message

Your LordAbbett.com password was successully updated. This page will be refreshed after 3 seconds.

OK

 

Health Care Fund

Summary

Summary

What is the Health Care Fund?

The Fund seeks to deliver long-term growth of capital by investing primarily in stocks of companies within the health care sector.

Fund Basicsas of 03/31/2021

Total Net Assets
$6.81 M
Inception Date
08/01/2019
Dividend Frequency
Monthly (Daily Accrual)
Fund Gross Expense Ratio
6.15%
Fund Net Expense Ratio
0.78%
Number of Holdings
87

Fund Expense Ratio :

Gross 6.15%

Net 0.78%

YTD 1-YR 3-YR 5-YR 10-YR Since Inception 07/31/2019
w/o sales charge 3.19% 42.57% - - - 27.60%
Lipper Category Avg. Health/Biotechnology Funds 3.80% 34.47% - - - -
MSCI ACWI Health Care Index (Net) 4.45% 21.30% - - - 19.24%

Fund Expense Ratio :

Gross 6.15%

Net 0.78%

Fund Expense Ratio :

Gross 6.15%

Net 0.78%

YTD 1-YR 3-YR 5-YR 10-YR Since Inception 07/31/2019
w/o sales charge -1.67% 52.39% - - - 25.46%
Lipper Category Avg. Health/Biotechnology Funds -0.06% 47.57% - - - -
MSCI ACWI Health Care Index (Net) 0.44% 30.21% - - - 17.49%

Fund Expense Ratio :

Gross 6.15%

Net 0.78%

INVESTMENT TEAM

Devesh Karandikar
Devesh Karandikar

Portfolio Manager & Research Analyst

25 Years of Industry Experience

Matthew R. DeCicco
Matthew R. DeCicco, CFA

Partner & Director of Equities

21 Years of Industry Experience

Supported By 19 Investment Professionals with 34 Years Avg. Industry Experience

Contact a Representative

To contact your representative, enter your zip code and select your channel below.

Performance

Performance

Fund Expense Ratio :

Gross 6.15%

Net 0.78%

YTD 1-YR 3-YR 5-YR 10-YR Since Inception 07/31/2019
w/o sales charge 3.19% 42.57% - - - 27.60%
Lipper Category Avg. Health/Biotechnology Funds 3.80% 34.47% - - - -
MSCI ACWI Health Care Index (Net) 4.45% 21.30% - - - 19.24%

Fund Expense Ratio :

Gross 6.15%

Net 0.78%

Fund Expense Ratio :

Gross 6.15%

Net 0.78%

YTD 1-YR 3-YR 5-YR 10-YR Since Inception 07/31/2019
w/o sales charge -1.67% 52.39% - - - 25.46%
Lipper Category Avg. Health/Biotechnology Funds -0.06% 47.57% - - - -
MSCI ACWI Health Care Index (Net) 0.44% 30.21% - - - 17.49%

Fund Expense Ratio :

Gross 6.15%

Net 0.78%

NAV Historical Prices

Date Net Asset Value

Portfolio

Portfolio

Portfolio Positioning as of 03/31/2021

  • The COVID-19 vaccine deployment and a rebound to normal economic activity are creating optimism among investors so far in 2021.  However, nearer term, investors continue to grapple with rising COVID infections and hospitalizations in various regions, which is leading to an increasing death rate and increased mobility restrictions globally. With this backdrop, the Fund continues to be invested in innovation through Biotechnology, Health Care Equipment and Supplies, Life Science Tools and Diagnostics, and Health Care Technology. While Pharmaceuticals and Healthcare Providers and Services remain underweight.
  • We modestly shifted some of the Fund’s exposure to biotechnology towards Life Science Tools and Diagnostics and Pharmaceuticals early in the quarter as healthcare procedure volume is expected to normalize in the coming months.
  • As we look towards the second quarter, concerns around Drug Price Reform and other policy changes may impact healthcare returns in the near term; however, we believe exposure to innovative companies aiding in the human experience will ultimately drive strong returns.
  • We have remained focused on our core principles as we monitor and adjust to the ever-changing environment caused by COVID-19 and the dynamic political landscape.

Portfolio Details as of 03/31/2021

Total Net Assets
$6.81 M
Number of Holdings
87
Weighted Average Market Cap.
70.7 B
P/B Ratio
7.0x
P/E Ratio
31.6x

Attribution Analysis 

Health Care Fund Benchmark Variance
Sector Avg. Weight Base Return Avg. Weight Base Return Stock Selection Group Weight Total

Contributors & Detractors as of  03/31/2021

Contributors

Holding Contribution
Gw Pharmaceuticals Plc 0.4%
Pacific Biosciences 0.3%
Abbott Laboratories 0.3%
Horizon Therapeutics Pu 0.3%
10x Genomics Inc 0.3%

Detractors

Holding Contribution
Sarepta Therapeutics In -0.4%
Berkeley Lts Inc -0.4%
Iovance Biotherapeutics -0.3%
Pulmonx Corp -0.3%
Mirati Therapeutics Inc -0.3%

Fees & Expenses

Fees & Expenses

Expense Ratioas of 04/30/2021

Fund Gross Expense Ratio Fund Net Expense Ratio
6.15% 0.78%

Fund Documents

Fund Documents

Download fund documents & literature, create email subscriptions, and place direct mail order

0Documents selected
Order
n/a
Portfolio Holdings 1Q
Publish Date:11/03/2015
n/a
Portfolio Holdings 3Q
Publish Date:11/03/2015
Summary Prospectus
Publish Date:11/03/2015
n/a
Statutory Prospectus
Publish Date:11/03/2015
n/a
Prospectus (XBRL)
Publish Date:11/03/2015
SAI
Publish Date:11/03/2015
Annual Report
Publish Date:11/03/2015
Semi-Annual Report
Publish Date:11/03/2015
Fact Sheet
Publish Date:11/03/2015
Commentary
Publish Date:11/03/2015

To order literature visit full website

You may add to your cart by selecting quantities in each row below.

No rows selected. Please Go back and select at least one fund document

 
Quantity
Quantity
Remove
Remove

Select funds to run a Morningstar Hypothetical Report.

    Please confirm your literature shipping address

    Please review the address information below and make any necessary changes.

    All literature orders will be shipped to the address that you enter below. This information can be edited at any time.

    Current Literature Shipping Address

    * Required field